Sequential Therapy versus Quadruple Therapy for H.pylori Eradication in Iran

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103183836N1

Enrollment

300

Registered

2011-08-13

Start date

2011-12-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Peptic ulcer. Condition 2: Gastritis. Gastric ulcer -Duodenal ulcer - erosion (acute) of stomach -erosion (acute) of duodenum Chronic gastritis, unspecified , Acute (erosive) gastritis with haemorrhage

Interventions

Intervention 1: Group I (n=150) will receive quadruple therapy (20 mg omperazole bid, 240 mg bismuth subcitrate bid, 1000 mg tetracycline bid and 500 mg metronidazole bid) for 14 days. Intervention 2

Treatment - Drugs

Group I (n=150) will receive quadruple therapy (20 mg omperazole bid, 240 mg bismuth subcitrate bid, 1000 mg tetracycline bid and 500 mg metronidazole bid) for 14 days

Group II (n=150) will receive sequential therapy (20 mg omp bid, 1000 mg amoxicillin bid for 5 days, follow by 20 mg omperazole bid, 500mg metronidazole bid, 500mg clarithromycin for the other 5 days

Eligibility

Sex/Gender

All

Age

14 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion: Patients older than 14 years of age with dyspepsia, gastrointestinal bleeding, history of post prandial fullness and vomiting, undertake endoscopy.Two biopsies of the antrum and gastric body will perform. Those patients who have a positive rapid urease test or histological evidence for H. pylori in the gastric mucosa will enroll. Exclusion:Patients with severe comorbidity, such as cirrhosis, kidney failure, severe heart disease, pregnancy, lactation and evidence of malignancy, a previous history of eradication of H. pylori, a history of NSAID use, alcohol consumption and H2 blocker or PPI in the past two weeks or who haVE receive antibiotics and bismuth subcitrate in the last month will be excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Eeradication helicobacter pylori. Timepoint: Four weeks. Method of measurement: Urea breath test.	—

Secondary

Measure	Time frame
Side effect. Timepoint: Three days. Method of measurement: Good, intermediate and poor assessed by physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdolrahim Masjedizadeh

Jondishapou Ahvaz University of Medical Sciences

masjedi_r@ajums.ac.ir+98 61 1337 6922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026